This page shows the latest Paxlovid news and features for those working in and with pharma, biotech and healthcare.
The agency’s latest guidance recommends the use of Pfizer’s Paxlovid (tirmatrelvir plus ritonavir), GSK’s Xevudy (sotrovimab) and Roche’s RoActemra (tocilizumab). ... Paxlovid has been recommended for adults who do not need supplemental oxygen
in the US or EU, including COVID-19 treatment Paxlovid and breast cancer drug Ibrance.
Included in the advice is a strong recommendation for the use of Pfizer’s Paxlovid (nirmatrelvir/ritonavir) in mild or moderate COVID-19 patients who are at high risk of hospitalisation.
targets. This includes Paxlovid (nirmatrelvir and ritonavir), an orally administered drug that should be given at the first sign of infection for the treatment of patients with mild-to-moderate
as Pfizer’s Paxlovid (tirmatrelvir plus ritonavir) for use in non-hospitalised settings.
The agreement with Global Fund is part of the company’s strategy for equitable supply and access of Paxlovid. ... In line with this, Pfizer is also working with UNICEF to supply 95 low-and-middle-income countries with four million courses of Paxlovid.
More from news
Approximately 10 fully matching, plus 10 partially matching documents found.
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...